Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings

  • Syros Pharmaceuticals Inc SYRS announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609.
  • Updated data demonstrated clinical activity in heavily pre-treated patients across multiple tumor settings.
  • The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
  • Thirteen patients (28.9%) achieved stable disease (SD), with six patients' tumor regressions of up to 20% across multiple tumor types.
  • The most substantial clinical activity was observed in heavily pre-treated patients with advanced pancreatic cancer.
  • Five of 13 (38.5%) evaluable patients achieved SD, with tumor reductions in two patients.
  • Reductions in the CA 19-9 tumor marker were observed in three of four pancreatic cancer patients. These reductions ranged from 32% to 72%.
  • One metastatic pancreatic cancer patient who had failed two prior lines of therapy and relapsed after the third line of treatment, experienced prolonged SD of up to 10 months.
  • Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for pancreatic cancer in Q4 of 2021.
  • The Company also plans to initiate a Phase 1b trial evaluating SY-5609 in combination with Bruton's tyrosine kinase (BTK) inhibitor for mantle cell lymphoma in 1H of 2022 the first half of 2022. 
  • Price Action: SYRS stock is down 2.36% at $4.96 during the market session on the last check Monday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Posted In: NewsPenny StocksSmall CapBriefsESMO21Phase 1 TrialSolid Tumor